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Case presentation
This 52-year-old woman was first admitted to the New Eng-
land Medical Center Hospital (NEMCH) for evaluation of hypo-
natremia. She was in good health until 6 weeks prior to admis-
sion when she began to experience fatigue, confusion, vomiting,
and transient diarrhea. There was no history of fever, chills,
weight loss, or anorexia, nor of cardiovascular, genitourinary, or
central nervous system symptoms. Two weeks before admis-
sion, she consulted her own physician. Physical examination was
not remarkable but laboratory studies disclosed: serum sodium
112 mEq, potassium 3.3 mEq, chloride 84 mEq, and bicarbonate
22 mEq per liter. Other laboratory values included: BUN 7 mg%,
serum creatinine 0.9 mg%, serum uric acid 1.5 mg%, calcium 9.3
mg%, phosphorus 3.4 mg%, total protein 6.5 g%, albumin 4.4
g%, bilirubin 0.9 mg%, and alkaline phosphatase 31 IU; the
SOOT, SGPT, and LDH were normal. Extensive evaluation by
the referring physician disclosed normal chest x-ray, upper gas-
trointestinal series, oral cholecystogram, barium enema, intra-
venous pyelogram, skull series, brain scan, and liver-spleen
scan. A bone scan revealed slight uptake in the mid-right cervical
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spine consistent with degenerative joint disease. Serum ACTH
levels were normal, as were TSH, cortisol, T3, and T4. Urinary
17-ketosteroids were 5.8 mg/day (normal 6-15 mg/day). Urinaly-
sis on three occasions revealed no red cells on one occasion but
30 to 40 cells on two other occasions. No red cell casts were
noted.
The patient's past medical and family histories were unre-
markable. She does not drink alcohol, had been taking no medi-
cations, and had no evident psychiatric disturbances. She
smoked two packs of cigarettes per day. The patient remained
hyponatremic with serum sodium concentrations as high as 133
mEq/liter following treatment with hypertonic saline and as low
as 117 mEq/liter when she was allowed free access to salt and
water. Plasma and urine osmolalities measured simultaneously
on two occasions were: Posm 240, U0,, 509 mOsm/kg; Posm 237
mOsm/kg, U05,, 490 mOsm/kg. Spot urine sodium determinations
revealed 30 to 140 mEq/liter. Urine output was as high as 3 to 4
liters per day. At no time was there evidence of volume deple-
tion.
The patient was treated with demeclocycline 1200 mg/day and
referred to NEMCH for further evaluation. On admission to
NEMCH, the patient was in no acute distress. Physical examina-
tion disclosed normal vital signs. Sun-exposed areas were pig-
mented. The remainder of the physical examination was unre-
markable. Laboratory studies revealed the hematocrit to be 38%
and the white blood cell (WBC) count 6000/mm3. Results of the
urinalysis revealed pH 5, no protein, specific gravity 1.014,0 to I
WBCs, and 0 to I RBCs. Urine cultures revealed no growth.
Serum electrolytes included: sodium 128 mEq, potassium 4.6
mEq, chloride 90 mEq, and bicarbonate 24 mEq per liter. The
BUN was 19 mg%, and the serum creatinine was 0.7 mg%. The
platelet count was 417,000; the prothrombin and partial thrombo-
plastin times were normal. Chest x-ray revealed no evidence of
lung or mediastinal masses. CT scans of the head were normal
as was a pancreatic echogram. The x-rays from the referring hos-
pital were obtained, reviewed, and found to be normal or non-
contributory. Cystoscopy revealed diffuse hyperemia with mod-
erate trabeculation but no bladder tumor, stone, or other cause
of hematuria.
Several days after demeclocycline was first administered, and
the patient's water intake also had been mildly restricted, the
serum sodium concentration increased to 147 mEq/liter and the
BUN and serum creatinine increased to 40 and 1.9 mg% respec-
tively. Demeclocycline therapy was discontinued and the pa-
tient's water intake was liberalized, with the result that serum
sodium concentration fell to 137 mEq/liter. Seven days after
withdrawal of demeclocycline, a water-loading test was carried
out in which 1200 ml of water was given by mouth in 20 minutes.
The Posm prior to the water load was 287 mOsm/kg and the Uosm
was 312 mOsm/kg. Serum sodium was 136 mEq, potassium 3.8
mEq, chloride 98 mEq, and CO2 29 mEq/liter. The urine output
in the 5'/2 hours following water ingestion was 630 cc. After 5
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hours the serum sodium was 133 mEq, potassium 3.8 mEq, chlo-
ride 96 mEq, and CO2 28 mEq/liter. The serum osmolality had
fallen to 280 mOsm/kg and the U0 had reached a low of 208
mOsm/kg. The patient was discharged on 300 mg demeclocycline
twice daily and was to be monitored by the referring physician.
The dose of demeclocycline was to be increased if required for
maintaining a normal serum sodium concentration. Six months
after initial presentation, the patient still has SIADH but has no
evidence of tumor.
Discussion
DR. MANUEL MARTINEZ-MALDONADO (Professor
of Medicine and Physiology, Director of Medical
Services, San Juan VA Hospital, and Visiting Pro-
fessor of Medicine, Peter Bent Brigham Hospital
Boston, MA): Hyponatremia, one of the most com-
mon electrolyte disturbances, results from dilution
of body sodium stores. The conditions that lead to
hyponatremia include: (I) administration or con-
sumption of fluids in excess of the ability of the
normal kidney to excrete them; (2) administration
of pharmacologic agents, particularly certain di-
uretics, sulfonamides, and antidepressants; (3)
edematous states (e.g., advanced congestive heart
failure, cirrhosis of the liver, nephrotic syndrome);
(4) reduced extracellular fluid volume; (5) various
endocrine disorders; and (6) the syndrome of inap-
propriate antidiuretic hormone secretion (SIADH).
I believe that the patient presented today, in fact,
has the syndrome of inappropriate antidiuretic hor-
mone (ADH) secretion. Before discussing SIADH
and the patient's problem, however, I plan to re-
view briefly the diagnostic approach to hyponatre-
mia and the regulation of renal water excretion.
Diagnostic approach. A simple classification of
hyponatremia has been suggested by Berl and
his collaborators [1]. A combination of clini-
cal and laboratory data are utilized to characterize
the patient with hyponatremia. The history and
physical examination identify most of the condi-
tions, but measurements of plasma as well as urine
sodium and osmolality also can be of great utility.
When plasma sodium is low and plasma osmolality
is normal, conditions such as hyperlipidemia and
hyperproteinemia are readily recognized. Salt-re-
taining states, such as heart failure, are character-
ized by very low urine-sodium concentrations (< 10
mEq/liter). By contrast, salt-losing states, as in pa-
tients receiving diuretic therapy or those with adre-
nal insufficiency, are characterized by high urine-
sodium concentrations (> 20 mEq/liter). If avail-
able, antidiuretic hormone assays of plasma or
urine should make it possible to establish a diagno-
sis beyond doubt. We shall return to these matters
later.
Regulation of renal ii'ater excretion. The major
regulator of renal water excretion is ADH. This oc-
tapeptide is secreted into the blood from its storage
sites in the posterior pituitary when changes in
plasma osmolality stimulate hypothalamic recep-
tors. Although ADH appears to have effects on the
renal vasculature, the systemic microcirculation,
and the reabsorption of sodium chloride and other
electrolytes, its major effect is that it increases the
water permeability of the distal nephron. This ac-
tion, manifested primarily by increased per-
meability of the collecting duct to water, permits
greater water reabsorption and ultimately leads to
the excretion of a small amount of highly concen-
trated urine. To induce this effect, ADH interacts
with a membrane receptor located in the con-
traluminal side of the cell. This interaction activates
adenylcyclase which, through a series of reactions
involving cyclic AMP and a protein kinase, is re-
sponsible for the increased water permeability.
Renal water excretion also depends on systemic
and renal hemodynamics. The autonomic nervous
system appears to be important in regulating ADH
secretion and water excretion [2]. Norepinephrine,
an alpha-adrenergic agonist, when infused intraven-
ously, causes an antidiuresis, whereas intravenous
isoproterenol, a beta-adrenergic agonist, causes a
diuresis [3]. The changes that mediate the release or
suppression of ADH appear to be the alterations in
vascular baroreceptors initiated by alpha- and beta-
adrenergic stimulation rather than any direct effects
of these agents. Many other vasoactive substances
such as angiotensin II and nicotine also affect ADH
release by way of arterial baroreceptors and the af-
ferent neural pathways.
Renal water excretion also can be affected by a!-
terations in renal hemodynamics independent of
ADH secretion. Reduction in glomerular filtration
rate (GFR) affects the filtered load of water and so-
dium. In turn, the quantity of sodium chloride that
reaches and is reabsorbed in the ascending limb of
Henle's loop (the diluting segment) is a critical de-
terminant of the volume of hypotonic or dilute tubu-
lar fluid that is formed in this segment and delivered
to the distal nephron [4, 5]. The quantity of solute-
'free" water excreted in the urine in the absence of
ADH is governed by the permeability of the collect-
ing duct to water. When the flow rate is low in the
distal nephron, water can be reabsorbed in the col-
lecting duct even if ADH is absent, and the urine
will be relatively concentrated. Therefore, any con-
556 Nephro/ogv Forum
dition that impairs renal hemodynamics and lowers
GFR (reducing the load of sodium chloride reaching
the diluting segment) or that yields a sustained se-
cretion of ADH will lead to impairment of urinary
dilution and consequently to water retention and di-
lution of body sodium stores. These considerations
suggest that a diagnosis of SIADH should not be
made in the presence of any condition that in itself
could lead to diminished diluting capacity, for ex-
ample, volume contraction. This assertion, how-
ever, does not necessarily imply that ADH is not a
factor in the hyponatremia present in these dis-
orders [6].
From the foregoing it is clear that renal water ex-
cretion can be impaired by many factors, including
sustained ADH secretion. The cause of the im-
paired water excretion in the patient presented
today and the disorder I will discuss in detail is the
syndrome of inappropriate ADH secretion.
Pathophysiologv ofSIADH. The syndrome of in-
appropriate ADH secretion was first clearly deline-
ated by William B. Schwartz and Frederic C. Bart-
ter [7]. Their classic description of 2 patients har-
boring bronchial cancer is, or should be, to the
nephrologist what Edvard Munch's expressionism
is to twentieth century painting. The fundamental
studies on which these investigators based their
clinical deduction were performed by Leaf and his
associates [8]. The exogenous administration of
vasopressin to normal humans was not accom-
panied by changes in body weight, serum sodium
concentration, or urinary sodium as long as water
intake was restricted. By contrast, free access to
water during administration of vasopressin led to
water retention, an increase in body weight, a fall in
serum sodium concentration and osmolality, and
natriuresis. Continued administration of ADH and
water for several days was attended by a return of
urine volume to baseline values and a fall in urine
osmolality. Subsequent studies in humans and dogs
have indicated that urine sodium excretion also re-
turns to baseline values [9, 10, 11]. Furthermore,
while urine volume, osmolality, and sodium con-
centration are maintained at values appropriate for
the level of fluid and salt intake, serum sodium and
osmolality remain low. Changes in urine sodium ex-
cretion following water restriction in patients with
SIADH clearly identify the relationship between
volume status and sodium losses. When fluid intake
is restricted and water loss ensues, urinary sodium
excretion falls and a sodium load is largely retained
[7]. When normal fluid intake is resumed, water is
retained, volume expands, and sodium excretion in-
creases [7]. However, the amount of water retained
during the development of the syndrome does not
always fully explain the hyponatremia, and during
water restriction, water loss usually is not sufficient
to account for the rise in serum sodium. This obser-
vation led Schwartz and Bartter to postulate that
osmotic inactivation" of intracellular solute might
occur, and that this inactivation is reversible upon
water restriction [7]. One study has suggested that
water loading might increase extrarenal solute loss-
es [12], but in another study cumulative sodium bal-
ance and aldosterone secretion rates in some pa-
tients with SIADH were negatively correlated with
water intake [13]. Thus, one can surmise that water
retention as well as solute loss or "inactivation"
contribute to the genesis of hyponatremia.
In addition to ADH, other hormones probably
play an important role in the pathophysiology of
SIADH. The contribution of mineralocorticoids in
maintaining salt and water balance in SIADH has
not been fully elucidated. Measurements of aldoste-
rone excretion and secretion in SIADH have been
equivocal [7, 12, 13, 14, 15]. Some reports have
claimed a rise, others a decrease, and others no
change. An interesting role for aldosterone in
SIADH has been reported by Lowance et al [15]
and Cohen et al [16]. Using dogs, these investiga-
tors have shown that maintenance of normal levels
of serum bicarbonate during chronic hypovolemic
volume expansion results from enhanced distal hy-
drogen ion secretion and that aldosterone secretion
is needed for this adaptive mechanism to ensue.
While concomitantly suggesting that severe chronic
hypotonicity might stimulate aldosterone secretion
despite volume expansion, these authors also have
advanced a plausible explanation for the observa-
tion that despite severe hyponatremia, serum bi-
carbonate remains normal in SIADH, as it did in the
patient discussed today.
Evidence indicates that angiotensin II might stim-
ulate ADH release by acting at some locus in the
central nervous system [17]. It is not clear, how-
ever, whether normal amounts of circulating angio-
tensin effect a change in ADH secretion. Although
circulating angiotensin might not lead to ADH re-
lease, it could potentiate ADH secretion in re-
sponse to other stimuli. For example, angiotensin
and hypertonic saline when injected into the third
ventricle of the brain of the conscious goat act syn-
ergistically to inhibit water diuresis [18]. I am not
aware of measurements of angiotensin II in SIADH
or what role angiotensin might play in the secretion
or release of ADH in the presence of hyponatremia.
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A group of hormones that also might influence
ADH secretion and action is the prostaglandins.
Prostaglandins of the E type (PGE) are antagonists
of the hydroosmotic effects of ADH both in vivo
[19] and in vitro [20]. Evidence is accumulating that
prostaglandins are synthesized in response to ADH
secretion and, because they might modulate the ef-
fect of ADH on water excretion, that they function
as a negative feedback inhibitor of ADH action. It is
interesting to speculate that hyponatremia might af-
fect the ability of the kidney to synthesize the
amounts of prostaglandins required for the negative
feedback. If so, prostaglandins could enhance the
effect of ADH and thus sustain water retention.
Further evidence for a role of prostaglandins in
SIADH comes from recent studies by Zusman and
coworkers [22]. This group produced sustained hy-
ponatremia in human volunteers by administering
indomethacin and ACTH. Indomethacin, of course,
is a potent prostaglandin inhibitor; ACTH indirectly
stimulates vasopressin-induced water flow because
the steroids secreted in response to this agent influ-
ence water flow in biologic membranes. The combi-
nation of indomethacin and ACTH reduced urine
volume, decreased free-water clearance, and in-
creased urine osmolality; as a consequence, weight
gain and hyponatremia occurred. Discontinuation
of ACTH was accompanied by a prompt diuresis
and restoration of a normal serum sodium concen-
tration. Berl et al showed that inhibition of prosta-
glandin synthesis enhances renal vasopressin action
in humans [23]. Because ACTH inhibits PGE bio-
synthesis [24] and reduces phosphodiesterase activ-
Table 1. Criteria for diagnosing SIADH
1. Serum hypoosmolality and hyponatremia
2. Urine that is less than maximally dilute
3. Urine sodium matches intake despite hyponatremia
4. Plasma ADH not suppressed
5. Absence of other causes of decreased diluting capacity
6. Improvement of renal sodium wasting with rigid water restric-
tion
ity [25], the combination of the two could markedly
increase the response to even low values of circulat-
ing ADH. This relationship is an attractive and fer-
tile field for investigation.
Diagnosis of SIADH. The patient presented
today had all of the features of SIADH (Table 1):
hypotonicity of the plasma, inappropriately concen-
trated urine, natriuresis in the presence of hypona-
tremia, and reversal of renal sodium wasting after
water restriction. In addition, her renal and adrenal
function were normal and other known causes of
water excreting defects were not evident. More
conclusive evidence for the diagnosis comes from
special studies. Infusion of hypertonic saline did not
fully correct the hyponatremia and, when the pa-
tient was allowed free water ad libitum, urine out-
put rose and both P0sm and Uosm fell. These findings
are characteristic of SIADH. Furthermore, the re-
sponse to ad libitum water ingestion was a preview
of the response to an acute water load [26]. This
patient's physician wisely waited to begin water
loading until after therapy had corrected her serum
sodium to normal levels. The response was clearly
abnormal: only 63% of the oral water load was ex-
creted in 5V2 hours (Table 2). Normal subjects ex-
crete more than 80% of the water load and their
Uosm falls to values less than 100 mOsm/kg in 5
hours [27]. A response similar to that of normal in-
dividuals is expected in patients in whom the os-
moreceptor has been reset" so that ADH release
is triggered at lower values of plasma osmolality
[28].
Another interesting feature manifested by this pa-
tient—hypouricemia—also might have diagnostic
value. Beck recently reported that in a group of
hyponatremic patients, all of those with SIADH had
hypouricemia (values of uric acid of 2.9 0.4 mg/
dl), whereas those with other causes of hyponatre-
mia had normal levels of serum uric acid [29]. The
mechanism for the hypouncemia seems to be in-
creased renal clearance of uric acid. Clearly, the hy-
Table 2. Water loading test
Date Time
Plasma
Na
rnEq//iter
Plasma
Osm
rnOsmlkg
Urine
Osm
,nOsmlkg
Urine
Vol
,nl
Plasma
ADHa
microunjjs/,n/
6/26 6:00AM 136 287 312 — 18
9:00-9:20 AM Water load 1200 ml
11:45AM 132 282 208
2:20PM 133 280 227 630 28.1
6/27 6:00 AM 136 282 227 — 7.3
a Normal" values for randomly hydrated patients said to be 0.4—5.3 microunits/mI (Nichols Institute, California).
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pouricemia in this patient must have resulted from
just such a phenomenon.
Perhaps one of the most exciting recent develop-
ments is the use of plasma assays of ADH for diag-
nostic purposes. Not until the development of ade-
quate assay procedures for vasopressin has it been
documented that the values of plasma vasopressin
in patients with SIADH are abnormally high rela-
tive to the hypotonicity of plasma [30—32]. Despite
this observation, absolute plasma hormone values
are not too different from those in healthy individ-
uals except in some cases of ectopic production of
the hormone by a tumor [31, 32]. Even sustained
normal ADH levels are inappropriate, of course,
because changes of 1% in plasma osmolality should
be accompanied by a change in plasma vasopressin
of about I pg!ml [33]. Furthermore, a change in
vasopressin of 1 pg/mi is accompanied by about a
50% change in the kidney's capacity to concentrate
the urine. Thus, at normal plasma osmolality, when
plasma vasopressin is between 2.0 and 2.5 pglml
and urine osmolality is about 500 mOsm/kg, a drop
in vasopressin by 1 pglml in response to a reduction
in plasma osmolality of 1% (2.9 mOsm/kg) would
reduce UOSrfl to 250 mOsm/kg and double the rate
of urine flow. Maintenance of normal values of plasma
vasopressin in the presence of severe hyponatremia
therefore is clearly pathologic.
Measurements of vasopressin in the urine also
can help in diagnosing ADH and water distur-
bances. A good correlation exists between blood
and urinary hormone measurements. Moreover,
urine hormone measurements have the added ad-
vantage of representing an integrated index of se-
cretion over time, whereas the plasma ADH level
represents a single point in time in a system in
which marked spontaneous fluctuations can occur
from moment to moment. Urine ADH is notably
higher in SIADH than in other hyponatremic condi-
tions [33].
Although patients with SIADH have vasopressin
levels within the normal range, these individuals ex-
hibit different patterns in plasma vasopressin titers
in response to hypertonic saline infusion. Four pat-
terns of response have been identified by Robertson
and his collaborators [34]. The type A pattern con-
sists of large, erratic changes in plasma vasopressin
with no relation to the plasma osmolality. Twenty
percent of patients with SIADH have this pattern.
Some have tumors and some do not. This pattern
suggests that osmoreceptor control and vasopressin
release are completely independent of each oth-
er. In this group, changes in vasopressin concentra-
tion occur either at random or in response to tran-
sient and erratic nonosmotic stimuli. In this group,
measurement of urine vasopressin is sometimes of
greater value than are random plasma measure-
ments. The values of ADH shown in Table 2 in-
dicate that the patient described here belongs to
type A.
Type B consists of patients who respond to hy-
pertonic saline with a prompt and progressive in-
crease in plasma vasopressin that correlates closely
with the rise in plasma osmolality. While the slope
of the regression line, which describes the relation-
ship between plasma osmolality and plasma vaso-
pressin, parallels the normal response, it intercepts
the osmolality axis at a value well below 275 mOsm/
kg, the lowest found in healthy adults. Clear-
ly, although the response is qualitatively normal,
the threshold of the receptor is set at abnormally
low values. Approximately 35% of patients with
SIADH have this pattern. The cause of this disorder
is not clear, but it occurs in a variety of conditions.
Patients with this pattern of response have certain
clinical characteristics not seen in other types of
SIADH. Specifically, since osmotic control of vaso-
pressin release is qualitatively normal, increased
water intake can eventually lead to maximum urine
dilution and perhaps a rate of urine output sufficient
to prevent further water retention. DeFronzo et al
[35] and Michelis et al [36] have reported patients
whose ability to handle water is exactly as predicted
by this analysis; these patients' responses are possi-
bly examples of a type-B osmoregulatory defect.
Patients classified as having type-C SIADH have
elevated plasma vasopressin values initially, but
when plasma osmolality passes the normal thresh-
old, vasopressin concentration starts rising appro-
priately in response to further increases in tonicity.
This pattern, which occurs in 35% of all patients
with SIADH, has been observed with basal skull
fractures, meningitis, and other diseases. The pat-
tern suggests that under hypotonic conditions a
constant, nonsuppressible release or bleak" of
vasopressin occurs despite otherwise normal os-
moreceptor function. In contrast to type B, SIADH
is present at all times in type C patients, because
maximal urinary dilution cannot be attained regard-
less of the degrees of water retention and hypotoni-
city.
Patients with type-D SIADH have vasopressin
levels that seem to be normally suppressed under
hypotonic conditions. Furthermore, the values do
not rise until plasma osmolality exceeds the normal
threshold value. The urine is persistently of a higher
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osmolality than the plasma; thus, the diluting defect
probably is not the consequence of abnormal vaso-
pressin release. Rather, renal insensitivity to the
hormone or the elaboration of some other anti-
diuretic factor might be present. Approximately
10% of patients are in this category.
Causes of SIADH. Let us now consider the cause
of hyponatremia in this patient. As I indicated ear-
lier, we can disregard causes such as volume con-
traction, cardiac failure, and renal disease. We also
can eliminate pseudohyponatremia secondary to
hyperlipidemia or hyperproteinemia because in
both of these conditions plasma osmolality is nor-
mal [37].
We will first consider the various endo-
crinopathies. The patient exhibited no evidence of a
major endocrine disorder. Thyroid deficiency was
not present, as indicated by the normal values of T3,
T4, and TSH. The possibility that ADH plays a role
in the hyponatremia of hypothyroidism is con-
troversial [38]. Evidence acquired in hypothyroid
rats with congenital absence of ADH indicates that
diminished GFR and reduced distal sodium chloride
delivery are the most important factors impairing
water excretion [39, 40]. In hypothyroid humans,
however, the administration of thyroid hormone is
associated with correction of hyponatremia well be-
fore GFR and distal delivery return to normal [41].
In the patient presented here, adrenal function
probably was intact because the plasma cortisol
level was normal. Although patients with primary
or secondary Addison's disease are unable to ex-
crete a water load and frequently develop hypona-
tremia, it has not been easy to identify the cause of
the water-excreting defect. Some researchers have
attributed the defective diluting capacity to defi-
ciency of mineralocorticoids and a resultant sodium
depletion and diminished distal delivery of sodium
chloride. Others have argued that glucocorticoid
deficiency is more important, and that this hormone
deficiency either augments ADH release or in-
creases distal tubular permeability to water. In
fact, diminished distal sodium chloride delivery
clearly contributes to the defect in urine dilution,
and considerable evidence indicates that increased
circulating levels of ADH also are present in addi-
sonian patients [42, 43]. Finally, in normovolemic,
adrenalectomized Brattleboro rats with congen-
ital absence of ADH, a persistent defect in urine di-
lution has been observed [44]. In such animals, re-
placement of both gluco- and mineralocorticoid is
needed to fully restore normal water excretion.
Thus, the defect in water excretion in the addisoni-
an patient is probably multifactorial. Reduction of
the extracellular fluid volume, alterations in system-
ic hemodynamics, increased ADH levels, and in-
creased permeability of the distal nephron to water
all seem to play a role. Although azotemia, hyper-
kalemia, acidosis, and volume depletion typically
occur in the patient with Addison's disease, some-
times only SIADH is manifested. Administration of
glucocorticoids either orally or intravenously
promptly induces a water diuresis and corrects the
hyponatremia of Addison's disease. Hyponatremia
secondary to sustained elevation of ADH is not cor-
rected by glucocorticoid therapy [45].
Let us now consider the disorders known to be
responsible for SIADH (Table 3). Could stress have
resulted in excessive ADH release in this patient?
Neither overt emotional stress nor physical stress
was present. In addition, when stress does cause
SIADH, hypoosmolality is short-lived [46]. In the
patient described here, an effort was made to dis-
card the possibility of the surreptitious intake of
medications, but we are cognizant of how difficult it
Table 3. Causes of SIADH
I. Tumors
1. Bronchogenic carcinoma
2. Adenocarcinoma of duodenum
3. Adenocarcinoma of pancreas
4. Carcinoma of ureter
5. Hodgkin's disease
6. Thymoma
II. Leukemias
III. Pulmonary disease
1. Tuberculosis
2. Pneumonia
3. Lung abscess
4. Aspergillosis with cavitation
5. Chronicchest infections
IV. Central nervous system disorders
1. Trauma
2. Subdural hematoma
3. Abscess
4. Meningitis
5. Encephalitis
6. Subarachnoid hemorrhage
7. Guillain-Barré syndrome
8. Acute intermittent porphyria
9. Systemic lupus erythematosus
10. Other CNS disorders
V. Stress
VI. Idiopathic (?)
Table 4. Drugs associated with SIADH
1. Vasopressin 6. Diuretics
2. Oxytocin 7. Clofibrate
3. Chlorpropamide 8. Carbamazepine
4. Vincristine 9. Fluphenazine
5. Cyclophosphamide 10. Amitryptyline
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can be to identify patients who medicate them-
selves. I will nevertheless assume, I hope safely,
that the patient was not receiving any of the drugs
listed in Table 4 prior to or after her arrival at this
institution. All of these drugs can cause hyponatre-
mia by stimulating ADH release or potentiating its
effect [47, 48]. One of the widely used drugs that
leads to severe hyponatremia is chlorpropamide.
This sulfonylurea decreases free-water clearance in
normal subjects and in patients with partial pituitary
diabetes insipidus. In vivo and in vitro evidence
suggests that chlorpropamide leads to hyponatre-
mia because it stimulates ADH release and poten-
tiates the renal action of submaximal doses of
ADH. Because plasma vasopressin does not change
after chiorpropamide administration in humans, the
antidiuretic properties of the drug seem to result
mostly from increased peripheral actions of ADH
[49].
An equally unlikely cause of increased ADH re-
lease in this patient in view of normal chest x-rays,
skull x-rays, and CT scan of the skull are brain masses,
tumors, or inflammatory diseases of the chest.
Finally, in some patients with SIADH, no cause
can be identified. I was able to find two such pa-
tients reported before 1967 [50, 51], whose diagnos-
tic workup did not include some of the very special
studies available today (e.g., CT scan). A child with
this syndrome also has been reported [52]. Forrest
et al described a patient in whom long-term follow-
up for 17 years failed to disclose a specific lesion
[53]. This patient and two others described recently
have exhibited hypertension [54, 55]. In addition,
abnormal thirst was present in both Forrest's [53]
and Whitaker's [54] patients. A hypothalamic lesion
might be present in these subjects and be respon-
sible for excess ADH secretion.
We always must be cautious about making a diag-
nosis of "idiopathic" SIADH. Although most of the
patient's complaints—fatigue, vomiting, and con-
fusion—might be attributable to hypoosmolality, di-
arrhea does not usually occur in low-serum-sodium
syndromes. We might invoke a viral disease with a
predilection for the gastrointestinal tract and the
central nervous system as the cause of this patient's
complaints. This hypothetical viral illness, as a con-
sequence of its central nervous system effects, how-
ever subtle, might have stimulated the secretion of
ADH, which resulted in the severe hyponatremia
that she exhibited prior to her internment in this in-
stitution. Nevertheless, the duration of the illness
makes this proposal unlikely.
We also must keep in mind that the cause of the
inappropriate ADH release might become evident
later. It is conceivable that SIADH might precede
overt disease, specifically cancer, just as the ne-
phrotic syndrome can pre-date Hodgkin's disease
and as the Fanconi syndrome can antecede multiple
myeloma by months or even years [56, 57]. I also
would like to mention another finding that might be
of critical importance in explaining the source of
antidiuretic material that finally produced severe
hyponatremia in our patient. I refer to the inter-
mittent microscopic hematuria observed. We are all
aware that carcinoma of the ureter can lead to in-
appropriate ADH secretion [58], but in view of the
absence of a clear-cut diagnosis, and despite a nor-
mal IVP, one should consider the possibility of a
hypernephroma thus further diagnostic studies, in-
cluding sonography, cystoscopy, and if necessary
arteriography, are warranted.
Clinical significance of hvponatrernia. The clini-
cal manifestations of patients with SIADH can re-
flect their underlying illness or the reduction in the
osmolality of the body fluids. The duration and se-
verity of the hyponatremia determine the extent of
symptoms. Symptoms of sustained hyponatremia
differ markedly from those of acute water intoxica-
tion. A fall in plasma sodium from 147 to 131 mEq/
liter induced over a period of approximately 10 days
is accompanied by constant thirst, impaired taste,
anorexia, and muscle cramps, and sometimes by
dyspnea on exertion and dullness of sensorium [59].
Reduction of serum sodium to 120 to 130 mEq/liter
can be associated with abdominal cramps, nausea,
and vomiting. More severe hyponatremia, i.e., so-
dium concentrations below 115 mEq/liter, can lead
to weakness, lethargy, restlessness, confusion, deli-
rium, and impaired orientation. At this level, mus-
cular twitching is often present and convulsions can
occur even though the reduction in sodium concen-
tration might have occurred gradually.
The hyponatremia of acute water intoxication
produces different symptoms, probably because of
the rapidity with which it occurs. Neurologic mani-
festions are not observed until plasma sodium has
fallen below 125 mEq/liter; these include nausea,
vomiting, muscular twitching, grand mal seizures,
and coma [60, 61]. When water intoxication occurs
in less than 24 hours and serum sodium falls below
125 mEq/liter, permanent brain damage is sub-
stantial and mortality is about 50%. As noted ear-
lier, even more severe degrees of hyponatremia can
be well tolerated if serum sodium falls gradually
over several days or weeks. However, neither the
absolute level of serum sodium nor the rate of its
fall correlate well with the occurrence of seizures or
other manifestations in experimental animals or in
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humans. Nevertheless, when plasma sodium is be-
low 120 mEq/liter, most patients have a depressed
sensorium and can have seizures.
Animal experiments in which serum sodium has
been reduced below values of 125 mEq/liter in ito 4
hours show that cerebral edema occurs. Such ani-
mals show only modest reductions in brain elec-
trolyte content. In experimental chronic hyponatre-
mia, brain water content is increased after 3 to 22
days of sustained hyponatremia, but in these ani-
mals brain sodium and chloride content are re-
duced, and these reductions can contribute to the
development of symptoms [62, 63]. Thus, although
the manifestations of acute hyponatremia appear to
be critically dependent on brain edema, chronic hy-
ponatremia is thought to be a manifestation of de-
creased brain electrolyte content. Sodium is essen-
tial for nerve and muscle excitability and contrib-
utes to synaptic transmission and generation of
action potentials. This ion is also involved in the
uptake and release of neurotransmitters in pre-
synaptic terminals and nerve endings. Brain tissue
ATP may be sustained at the expense of phospho-
creatine since this compound is markedly dimin-
ished in hyponatremia. Reduction in phosphocrea-
tine, the source of ATP, under these circumstances
might lead to failure of ATP production, which
would reduce brain energy metabolism and inter-
fere with neurotransmitter amino acid release at the
synapse. These changes are perhaps responsible for
many of the clinical manifestations of hyponatre-
mia.
Management of SIADH. Elimination of the cause
of the release of antidiuretic material, when pos-
sible, and fluid restriction are the cornerstones of
therapy for SIADH. Acute symptomatic hyponatre-
mia always requires therapy, the aggressiveness of
which depends on the clinical condition of the pa-
tient. When hyponatremia is due to a specific under-
lying cause, therapy should be directed at that par-
ticular process. When severe symptoms are pres-
ent, hypertonic saline administration is necessary.
This form of treatment alone, however, is usually of
little value in SIADH because, in the presence of
volume expansion and a normal GFR, rapid excre-
tion of sodium will permit only transient and modest
elevations of serum sodium. However, if one in-
duces negative water balance by the use of potent
loop diuretics such as furosemide, and replaces uri-
nary electrolyte losses using 3% saline, the serum so-
dium concentration will rise rapidly [64]. In most
situations, restriction of fluid intake below the com-
bined total of insensible losses and urine output is
an appropriate approach.
The observation that some drugs induce nephro-
genic diabetes insipidus has permitted their in-
clusion in the therapeutic armamentarium of
SIADH. Two such drugs are lithium and deme-
clocycline. Lithium, which is used extensively in
the therapy of affective disorders, induces polyuria
in normal people. The polyuria of lithium intoxica-
tion is unresponsive to exogenous vasopressin ad-
ministration and is characterized physiologically by
normal free-water clearance (CH20) in the absence of
ADH, and markedly impaired free-water reabsorp-
tion (TH20) in the presence of ADH; both reactions
indicate a direct renal effect [48, 65]. Further evi-
dence that lithium directly affects the kidney can be
adduced from the observation that chiorothiazide
reduces the polyuria, a response expected in neph-
rogenic diabetes insipidus but not in primary or psy-
chogenic polydypsia [65, 66].
The mechanism by which lithium increases renal
water excretion does not depend on a reduced med-
ullary osmotic gradient. The normal corticomedui-
lary gradient is maintained in rats and dogs [67, 68].
Furthermore, in rats [67, 69] and in humans [66]
CH2O is normal; this finding suggests that sodium
chloride reabsorption in the ascending limb and
distal tubule is essentially unchanged.
A majority of the studies concerning lithium dem-
onstrate that it impairs the capacity of ADH to stim-
ulate osmotic water flow in the rat [67, 69] and toad
urinary bladder [70, 71]. Depending on the concen-
tration, lithium can block ADH-induced water flow
without interfering with cyclic AMP-induced water
flow. If concentrations of lithium are high enough,
however, dibutyryl cyclic AMP effects also are
blocked [67]. Similar results, observed in the rat in
vivo [67, 69], suggest that lithium blocks ADH ef-
fects at steps both proximal and distal to cAMP for-
mation. Lithium also inhibits ADH-induced ade-
nylcyclase activity when added to homogenates of
renal medulla from humans or rats [67].
Demeclocycline (DMC) is known to induce neph-
rogenic diabetes insipidus in humans. Such individ-
uals preserve the ability to attain a normal minimal
urine osmolality. This, together with the finding of
normal CH2O, suggests that distal sodium chloride
reabsorption is normal [72]. Administration of DMC
in high doses (1200 mg/day) has been necessary to
induce a concentrating defect, but it is not effective
in all subjects. Lower doses (600 mg/day) produce a
partial effect. In neither case is the defect respon-
sive to administration of exogenous vasopressin.
Demeclocycline inhibits ADH-induced osmotic wa-
ter flow in a dose-responsive and reversible man-
ner. When placed in the serosal side of toad urinary
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bladders, DMC inhibited both ADH-induced and
cyclic AMP-induced water flow [73, 74]. Thus,
DMC must have inhibitory effects at sites distal to
adenylcyclase activation and cyclic AMP gener-
ation. In human renal medullary tissue, DMC inhib-
its adenylcyclase activity and cyclic AMP-depen-
dent protein kinase [75].
Lithium and DMC have been used successfully in
the treatment of chronic SIADH [76, 77]. Unfortu-
nately, the response to lithium is variable [53].
Many complications have been attributed to this
agent, including acute renal failure, hyperosmolar
states, chronic nephropathy, central nervous sys-
tem alterations, cardiotoxicity, and thyroid dys-
function [53, 78-81]. On the other hand, DMC pro-
duces dose-dependent inhibition of ADH without
inducing undesirable central nervous system effects
[53]. It is effective in tumor-induced SIADH and in
other hyponatremic states [8 1-84]. But DMC must
be used with caution, or perhaps not at all, in pa-
tients with liver disease. Because the drug is metab-
olized in the liver, it can be retained in the plasma
and toxic nephropathy with renal failure can super-
vene [85—87]. The danger of renal failure is in-
creased in volume-contracted patients. In some pa-
tients, renal blood flow and GFR return to normal
when DMC is discontinued. Other side effects that
occur with DMC, as with other tetracyclines, in-
clude photosensitivity, gastrointestinal distur-
bances, and superinfection.
The response of this patient to DMC is compat-
ible with SIADH or with the blocking of the effect
of some other antidiuretic substance on the kidney.
The rise in BUN and serum creatinine observed in
this patient are undoubtedly related to the deme-
clocycline. This effect (at least the rise in BUN) is
explained by the well-known catabolic effects of the
tetracyclines. Also, pigmentation of sun-exposed
areas might be a manifestation of tetracycline tox-
icity.
Because both DMC and lithium have their major
effects on the target organ for antidiuretic hormone,
it is unlikely that they significantly alter the circulat-
ing titers of hormone. A drug that has been shown
to inhibit the release of ADH from the hypophysis,
and which has been used in the treatment of chronic
SIADH, is phenytoin [88]. One patient with
SIADH, probably secondary to a basilar skull frac-
ture, has been treated with phenytoin for 8 months
with reversal of clinical and laboratory findings of
SIADH and with no untoward side effects [88]. Fur-
ther trials with this drug seem warranted.
Questions and answers
DR. JEROME P. KASSIRER: In this patient, even be-
fore plasma levels of ADH were available, all of the
physiologic features that comprise the syndrome of
inappropriate ADH secretion were satisfied: so-
dium excretion in the presence of hypotonicity im-
plied that the patient was volume expanded, and the
increased filtration rate—evidenced by the low
serum creatinine, BUN, and serum uric acid—add-
ed further evidence for such expansion. Hypotonic
expansion in the absence of edema is consistent
with primary water retention. Thus, the diagnosis of
SIADH was assured. We thought this patient un-
usual because the cause of the SIADH was not im-
mediately apparent. We have treated many patients
who have had SIADH over the years; almost in-
variably, the cause is obvious. Patients usually have
oat cell carcinoma of the lung, a pulmonary lesion
such as tuberculosis or pneumonia, a central ner-
vous system lesion, or a history of treatment with a
drug such as chlorpropamide or cyclophosphamide.
In this patient no cause was discovered even after a
detailed, costly search. I have two questions: How
far should one go in studying such patients when the
cause is not immediately evident? What is the long-
term follow-up of similar patients, that is, what
cause usually emerges over time in patients with
idiopathic" SIADH?
DR. MARTINEZ: As I mentioned earlier, I would
perform a sonogram of this lady's kidneys to be
sure she does not have a hypernephroma. As far as
I know, only one adult patient has been reported to
have had inappropriate ADH for over 20 years. Her
response to demeclocycline suggests that she has
sustained SIADH. In fact, she is one of the patients
reported by Forrest et a! in the New England Jour-
nal of Medicine [53]. She develops persistent hypo-
natremia if she drinks water, and no specific cause
for that has ever been found. The patient described
today still might turn out to have some intracranial
abnormality, but as far as I know Forrest's patient
with SIADH is the only one who has been followed
that long without a diagnosis. As you pointed out,
one can usually arrive at a specific diagnosis. Since
the nephrotic syndrome and Fanconi's syndrome
can precede cancer, it is conceivable to me that the
patient under discussion might later on manifest an
obvious cause that is not evident now.
DR. CECIL COGGINS (Chief, Renal Unit, Massa-
chusetts General Hospital): I am curious about the
physiologic mechanisms responsible for the natriur-
esis that occurs at the onset of SIADH. The
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changes in aldosterone secretion are interesting, but
appear not to account for the natriuresis.
DR. MARTINEZ: As I recall from the study by Co-
hen et al, the aldosterone changes occur after so-
dium excretion has started [16]. In other words, al-
dosterone secretion is not increased initially. Clear-
ly, part of the explanation for natriuresis is volume
expansion. Earley et al showed some time ago that
water administration alone can depress proximal
reabsorption [89]. Thus, volume expansion is un-
questionably one mechanism by which SIADH in-
duces a sodium diuresis. Although not the only
mechanism, it is a major contributory factor. This
role for volume expansion also is supported by the
data from Cooke and his collaborators to which I
have already alluded [13]. I also have mentioned the
possible role of prostaglandins, but let me make this
free association: it has been said that a normal stim-
ulus for ADH secretion leads to prostaglandin syn-
thesis by the kidney. Prostaglandins are part of a
feedback mechanism, as they inhibit the hydro-
osmotic effect of ADH. We also know that local se-
cretion of prostaglandins can cause renal vasodila-
tion and natriuresis. Therefore, prostaglandins
might be a major mechanism by which natriuresis
occurs in SIADH. In fact, the study by Zusman that
I described earlier seems to support this notion
since the administration of indomethacin—which
inhibits prostaglandin synthesis—and ACTH—
which potentiates the effect of ADH—produced a
syndrome that mimicked SIADH [22]. Part of the
natriuresis, then, might depend on the intrarenal in-
teraction of some hormones.
DR. COGGINS: If humans or animals are given pi-
tressin and water, they gain weight and become
hyponatremic. Then they have a natriuresis and the
weight tends to come back down toward, but not
completely to, normal. I am curious about what
happens to salt and water balance after day 3, 4, or
5. Does the natriuresis continue after 4 or 5 days
thus suggesting some mechanism that is slower than
aldosterone or prostaglandins? In other words, is
there a natriuretic mechanism that is slow but quite
sensitive that will eventually return body weight
and fluid volume almost to normal and allow all
these other quicker mechanisms to return to nor-
mal?
DR. MARTINEZ: These patients seem to have al-
tered responses to water loads; this might explain
early or late natriuretic responses. There is an old
study by Ladd in which normal volunteers were giv-
en a water load one day, and given a salt load the
following morning [90]. People generally respond
sluggishly to a salt load, yet these subjects excreted
the salt loads rapidly and briskly. Patients with
SIADH behave in a similar fashion. If given saline,
they respond as if their volume tone" was primed
to eliminate the excess salt. Regardless of the ADH
concentration, they regulate salt excretion extreme-
ly well, particularly on a high-salt intake.
DR. KASSIRER: As I recall, the patients that were
studied by Schwartz and Bartter showed a natri-
uretic response only to the initial volume expansion
[26]. I do not remember any delayed natriuretic re-
sponse or second peak in sodium excretion.
DR. JORDAN J. COHEN: Yes, no second wave of
natriuretic response occurs. There is an escape from
the water-retaining effects of ADH that is analogous
to the phenomenon of DOCA escape. When pitres sin
and water are continually administered, water is re-
tained only transiently; urine volume begins to in-
crease after a few days despite the continued pres-
ence of ADH. The mechanism for this "escape"
has not been clarified. In any event, the stimulus to
aldosterone secretion becomes evident only after
moderately severe hyponatremia has occurred.
Earlier, the volume-expanding effects of water re-
tention suppress aldosterone secretion.
DR. MARTINEZ: I still believe that the natriuresis
in SIADH is a combination of volume expansion by
water retention, inhibition of aldosterone secre-
tion—at least initially—and intrarenal hormone in-
teractions.
DR. C0GGIN5: Where in your scheme of over-
salted, over-watered, slightly-over-watered, and un-
der-salted would you classify patients taking thia-
zides who are potassium depleted, such as those
whom Fichman described [45]?
DR. MARTINEZ: I would put those patients in the
volume-contracted group. I surmise that if you just
give those patients salt and take away the diuretic,
their salt and water balance will return to normal.
DR. KASSIRER: I always have had difficulty ac-
cepting volume contraction as the explanation for
water retention in that group of patients. These indi-
viduals typically have normal blood pressures, nor-
mal skin turgor, and BUN values of 10 to 14 mg%
and serum creatinine of 0.6 to 0.8 mg%. All of
these features point to volume expansion, not con-
traction. Fichman et al, who described the best-
studied group of these patients, attributed the dis-
turbance in water metabolism to potassium defi-
ciency; but given the observation by Cohen and
Schwartz that ADH-induced volume expansion
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yields a kaliuresis [16], perhaps the potassium defi-
cit is only an effect of volume expansion rather than
a cause. Is it conceivable that water retention could
be a function of the diuretic molecule itself'?
DR. MARTINEZ: The effects of thiazides and other
diuretics have been examined in toad bladders and
isolated perfused tubules. The only effect found so
far is that diuretics inhibit the hydroosmotic effect
of ADH [91]. Abramow has studied ethacrynic acid
in cortical collecting ducts, but this substance also
inhibits ADH-induced water flow [92].
DR. KASSIRER: This syndrome has been de-
scribed mostly with thiazides, not ethacrynic acid.
DR. MARTINEZ: True, but there is little evidence
to indicate that thiazides potentiate the effect of
ADH.
DR. KASSIRER: Do you agree then that potassium
deficiency leads to water retention?
DR. MARTINEZ: Hypokaleniia does not necessari-
ly reduce GFR, but it diminishes sodium chloride
transport in the loop of Henle [93].
DR. KASSIRER: How do you reconcile these ef-
fects of potassium deficiency with the classic stud-
ies of Relman and Schwartz? They showed that the
GFR was reduced in patients who were severely po-
tassium depleted secondary to intestinal potassium
losses and that the decrease in GFR was largely cor-
rected by potassium repletion [94].
DR. MARTINEZ: I believe that those patients were
severely volume contracted.
DR. KASSIRER: My recollection is that there was
no evidence of volume depletion in these patients.
DR. C0GGINs: So you are not convinced that
there is a group of patients with diuretic-induced
SIADH that is independent of volume contraction?
DR. MARTINEZ: I would have to see a good bal-
ance study on those people to be sure that after the
diuretic has been withdrawn, the SIADH reverts in
the absence of potassium repletion.
DR. COGGINS: So you are saying that potassium
deficiency is sufficient to increase ADH secretion in
patients who are volume contracted?
DR. MARTINEZ: I am saying that diuretic-induced
potassium deficiency and hyponatremia are part of
a continuum. The person who is taking a diuretic
becomes volume contracted and drinks water be-
cause of thirst. Since the individual is taking a di-
uretic, some salt will still be excreted, but the person
will retain water—as do patients with central diabe-
tes insipidus and nephrogenic diabetes insipidus—
and will become reexpanded with water. In addi-
tion, these people might become potassium
deficient. Hypotonic volume expansion might sus-
tain normal or high GFRs despite potassium defi-
ciency.
DR. JOHN T. HARRINGTON: Do you think that the
volume depletion is severe enough to account for
the water retention?
DR. MARTINEZ: Yes.
DR. HARRINGTON: I believe there is some infor-
mation suggesting that hypokalemia leads to an in-
crease in water ingestion.
DR. MARTINEZ: Those patients do drink more
water than they ought to, but their water intake
might be caused by volume contraction and potas-
sium deficiency.
DR. DAVID BUSHINSKY (Renal Fellow,
NEMCH): In Arieff's recent study, he suggests ag-
gressive treatment of hyponatremia, even in asymp-
tomatic patients whose serum sodium levels are less
than 115 mEq/liter, because of the possibility of fu-
ture neurologic damage [62]. He bases his opinion
on his studies in animals. Do you believe that ag-
gressive treatment is warranted for patients with
asymptomatic yet severe hyponatremia?
DR. MARTINEZ: Yes. If the serum sodium is be-
low 115 mEq/liter, the patient usually has symptoms.
At that point, the brain stores of sodium and potas-
sium are probably very low and these depletions
could interfere with brain function. Other sub-
stances required by nervous system tissue also
could be depleted, for example, ATP. If severe
hyponatremia is present, the patient, even without
severe symptoms, might not be able to perform
normally. Therefore I think treatment is necessary
under those circumstances.
DR. BUSHINSKY: I was specifically referring to
the asymptomatic patient with a severe depression
of serum sodium concentration. Do you think ag-
gressive therapy is warranted under such circum-
stances?
DR. MARTINEZ: I would find out what the cause is
and first try to correct or eliminate it. I would not
start an acute furosemide diuresis, if that is what
you mean by aggressive therapy.
DR. KASSIRER: Does convincing evidence exist to
confirm your assertion that hyponatremia can cause
permanent brain damage in adults? It seems to me
that it would often be very difficult to separate out
the other factors affecting the patient, such as car-
diac failure, hypoxemia, meningitis, metastatic dis-
ease, and skull fractures. I would be concerned
about attributing permanent neurologic damage to a
transient dilutional state, with the possible ex-
ception of extreme hypotonicity.
DR. MARTiNEZ: Yes, I think you are right. If I
had a patient as described by Dr. Bushinsky, I
would correct the sodium to a reasonable level. If
the patient did not improve, I would refrain from
instituting procedures that cause rapid, acute
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changes in sodium concentration; I think these
might do more harm than good.
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Addendum
Dr. Martinez' suggestion that the patient de-
scribed in the case report might be found later to be
suffering from a malignancy has been confirmed.
Although a chest x-ray one month after the patient
left the NEMCH was normal, another study 6
months later, when the patient presented with res-
piratory symptoms, demonstrated an infiltrate at
the right base and an enlarged right hylum. Me-
diastinoscopy disclosed enlarged nodes in this
region, and a lymph node biopsy showed small cell
carcinoma. The SIADH has persisted. In this
patient, therefore, 7 months elapsed between the
presentation of SIADH and the discovery of the
lung tumor; the tumor evaded detection despite
repeated chest x-rays and a CT scan carried out
approximately one month after manifestations of
ADH excess first appeared.
Reprint requests to Dr. M. Martinez-Maldonado, Renal
Division, Peter Bent Brigham Hospital, 721 Huntington Ave.,
Boston, MA 02115 USA.
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